VRDN Stock Overview
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases.
Notes are coming soon
Viridian Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$35.80|
|52 Week High||US$39.00|
|52 Week Low||US$9.47|
|1 Month Change||30.37%|
|3 Month Change||88.62%|
|1 Year Change||79.09%|
|3 Year Change||186.00%|
|5 Year Change||-56.61%|
|Change since IPO||-80.28%|
Recent News & Updates
Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?Jan 08
Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large MarketSep 09
Viridian Therapeutics board compensation committee approves inducement grantsSep 02
An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% UndervaluedAug 22
Viridian Therapeutics Q2 2022 Earnings PreviewAug 12
Viridian Therapeutics gets a new COOJun 23
Viridian Therapeutics (VRDN) Investor Presentation - SlideshowJun 08
Viridian Therapeutics reports Q1 resultsMay 06
Miragen: Viridian Therapeutics Acquisition Offers Good Speculative Entry OpportunityDec 08
|VRDN||US Biotechs||US Market|
Return vs Industry: VRDN exceeded the US Biotechs industry which returned 4.3% over the past year.
Return vs Market: VRDN exceeded the US Market which returned -9.6% over the past year.
|VRDN Average Weekly Movement||9.0%|
|Biotechs Industry Average Movement||12.0%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||17.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: VRDN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: VRDN's weekly volatility (9%) has been stable over the past year.
About the Company
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.
Viridian Therapeutics, Inc. Fundamentals Summary
|VRDN fundamental statistics|
Is VRDN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VRDN income statement (TTM)|
|Cost of Revenue||US$83.97m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.81|
|Net Profit Margin||-6,009.30%|
How did VRDN perform over the long term?See historical performance and comparison